Your browser is no longer supported. Please, upgrade your browser.
Cidara Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.80 Insider Own1.30% Shs Outstand44.17M Perf Week-16.52%
Market Cap90.71M Forward P/E- EPS next Y-1.61 Insider Trans16.69% Shs Float35.34M Perf Month-18.70%
Income-74.90M PEG- EPS next Q-0.26 Inst Own54.50% Short Float5.11% Perf Quarter-26.67%
Sales12.10M P/S7.50 EPS this Y-27.60% Inst Trans0.08% Short Ratio1.82 Perf Half Y-26.38%
Book/sh0.24 P/B7.79 EPS next Y-12.20% ROA-106.40% Target Price- Perf Year-41.93%
Cash/sh0.74 P/C2.53 EPS next 5Y- ROE-221.20% 52W Range1.82 - 4.45 Perf YTD-6.50%
Dividend- P/FCF- EPS past 5Y5.10% ROI-405.90% 52W High-57.98% Beta1.35
Dividend %- Quick Ratio1.50 Sales past 5Y- Gross Margin- 52W Low2.75% ATR0.16
Employees79 Current Ratio1.50 Sales Q/Q105.60% Oper. Margin- RSI (14)33.01 Volatility7.22% 6.05%
OptionableYes Debt/Eq0.65 EPS Q/Q-44.40% Profit Margin- Rel Volume0.70 Prev Close2.01
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume991.11K Price1.87
Recom1.70 SMA20-13.39% SMA50-19.63% SMA200-30.37% Volume717,988 Change-6.97%
Mar-04-21Initiated Aegis Capital Buy $9
Sep-04-19Upgrade Wedbush Neutral → Outperform $2 → $4
Jul-26-18Initiated Citigroup Buy $8
Apr-21-17Initiated Raymond James Strong Buy
Apr-17-17Reiterated H.C. Wainwright Buy $18 → $14
Apr-12-17Initiated Ladenburg Thalmann Buy $11.25
Apr-11-17Resumed Wedbush Outperform $13
Feb-22-17Upgrade WBB Securities Sell → Hold $7.25
Feb-22-17Reiterated H.C. Wainwright Buy $25 → $18
Dec-21-16Resumed Leerink Partners Outperform
Dec-19-16Initiated H.C. Wainwright Buy $25
Sep-23-16Downgrade WBB Securities Hold → Sell $10.50
Oct-09-15Upgrade WBB Securities Sell → Hold $13
May-11-15Initiated Wedbush Outperform $22
May-11-15Initiated Needham Buy $20
May-11-15Initiated Leerink Partners Outperform $24
May-11-15Initiated Jefferies Buy $25
Apr-23-15Initiated WBB Securities Sell $13
May-05-21 03:00PM  
Apr-14-21 06:09AM  
Apr-07-21 08:00AM  
Apr-06-21 09:53AM  
Apr-05-21 08:05AM  
Apr-01-21 08:00AM  
Mar-05-21 09:24AM  
Mar-03-21 08:00AM  
Feb-28-21 01:11AM  
Feb-25-21 04:47PM  
Feb-17-21 10:04AM  
Feb-11-21 08:00AM  
Jan-25-21 08:00AM  
Jan-14-21 12:03AM  
Jan-05-21 04:59PM  
Dec-15-20 08:00AM  
Dec-07-20 10:57PM  
Dec-01-20 08:00AM  
Nov-30-20 08:00AM  
Nov-16-20 08:00AM  
Nov-15-20 07:35AM  
Nov-12-20 11:58AM  
Nov-11-20 04:05PM  
Nov-05-20 09:00PM  
Nov-01-20 08:41AM  
Oct-29-20 12:35PM  
Oct-21-20 08:00AM  
Oct-13-20 08:00AM  
Sep-14-20 08:00AM  
Sep-11-20 09:58AM  
Sep-02-20 08:19AM  
Aug-13-20 06:05PM  
Aug-04-20 08:00AM  
Jul-27-20 08:00AM  
Jul-19-20 10:02AM  
Jul-17-20 08:00AM  
Jul-05-20 10:02PM  
Jun-29-20 08:00AM  
Jun-23-20 08:00AM  
Jun-11-20 08:00AM  
Jun-04-20 09:33AM  
May-20-20 08:45AM  
May-13-20 06:05PM  
May-05-20 04:30PM  
Apr-28-20 08:00AM  
Apr-07-20 08:00AM  
Mar-31-20 12:00PM  
Mar-04-20 07:30AM  
Feb-27-20 12:00PM  
Feb-18-20 08:00AM  
Feb-12-20 05:30PM  
Feb-11-20 06:25AM  
Jan-22-20 07:55AM  
Jan-16-20 07:02AM  
Jan-10-20 08:00AM  
Dec-20-19 10:22AM  
Dec-13-19 05:38AM  
Dec-03-19 08:00AM  
Nov-18-19 08:00AM  
Nov-07-19 09:17PM  
Nov-05-19 08:00AM  
Oct-06-19 08:22PM  
Oct-03-19 10:22AM  
Oct-01-19 10:07AM  
Sep-16-19 04:05PM  
Sep-04-19 02:37PM  
Sep-03-19 12:31PM  
Aug-21-19 08:00AM  
Aug-08-19 04:07PM  
Aug-07-19 07:30AM  
Jul-29-19 07:00AM  
Jul-01-19 09:13AM  
Jun-20-19 11:13AM  
Jun-19-19 01:16PM  
Jun-07-19 09:27AM  
Jun-05-19 08:00AM  
May-22-19 09:00AM  
May-09-19 07:54PM  
Apr-16-19 08:00AM  
Apr-15-19 08:00AM  
Apr-12-19 10:08AM  
Apr-03-19 04:04PM  
Mar-26-19 08:00AM  
Mar-07-19 08:00AM  
Mar-04-19 12:19PM  
Feb-28-19 04:24PM  
Feb-05-19 08:00AM  
Jan-17-19 10:00AM  
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel long-acting anti-infectives for the treatment and prevention of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Abdollahian NeilChief Business OfficerApr 01Sale2.661,4693,90857,471Apr 05 06:24 PM
Daruwala PaulChief Operating OfficerApr 01Sale2.665931,57750,531Apr 05 06:17 PM
Oien JessicaGeneral Counsel & SecretaryApr 01Sale2.661,1773,1317,764Apr 05 05:35 PM
Abdollahian NeilChief Business OfficerJan 05Sale2.062,8685,90855,440Apr 05 06:24 PM
Daruwala PaulChief Operating OfficerJan 05Sale2.062,8685,90849,724Apr 05 06:17 PM
Oien JessicaGeneral Counsel & SecretaryJan 05Sale2.068241,6976,141Apr 05 05:35 PM
Stein JeffreyPresident & CEONov 10Buy2.0050,000100,015347,878Nov 12 06:00 AM
Levine James E.Chief Financial OfficerNov 10Buy2.0150,000100,72050,000Nov 12 06:00 AM